RNAC FY 2022 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$111M+30.2% YoY

Gross Profit

$109M98.2% margin

Operating Income

$15M13.1% margin

Net Income

$35M31.9% margin

EPS (Diluted)

$3.00

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$33M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$166M

Total Liabilities

$72M

Stockholders' Equity

$94M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$111M	$85M	+30.2%
Gross Profit	$109M	$85M	+27.8%
Operating Income	$15M	-$5M	+416.2%
Net Income	$35M	-$26M	+237.7%